Quantum Biopharma Ltd. (NASDAQ:QNTM) Short Interest Up 85.7% in May

Quantum Biopharma Ltd. (NASDAQ:QNTM) saw a significant growth in short interest in the month of May. As of May 29th, there was short interest totaling 411,604 shares, a growth of 85.7% from the May 14th total of 221,665 shares. Based on an average daily volume of 620,229 shares, the days-to-cover ratio is currently 0.7 days. Approximately 11.8% of the company’s shares are short sold.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new stake in shares of Quantum Biopharma in the 4th quarter valued at approximately $76,000. Jane Street Group LLC acquired a new position in shares of Quantum Biopharma during the fourth quarter worth $80,000. Finally, Platform Technology Partners purchased a new position in Quantum Biopharma in the first quarter valued at $199,000. Hedge funds and other institutional investors own 1.24% of the company’s stock.

Quantum Biopharma Trading Down 1.6%

Shares of NASDAQ QNTM opened at $3.64 on Wednesday. The stock has a market cap of $13.90 million, a P/E ratio of -0.44 and a beta of 0.36. Quantum Biopharma has a 12-month low of $2.07 and a 12-month high of $38.25. The business’s fifty day simple moving average is $4.97 and its 200-day simple moving average is $5.52.

Quantum Biopharma (NASDAQ:QNTM) last released its earnings results on Thursday, March 26th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.49).

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on QNTM shares. Weiss Ratings cut Quantum Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 28th. Wall Street Zen cut Quantum Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.